TEVATEVA PHARMACEUTICAL INDUSTRIES LTDvs its industry peers
A metric-by-metric comparison of TEVA PHARMACEUTICAL INDUSTRIES LTD against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEVAThis | $48.1B#1 | 68.7x#1 | 6.2x#2 | 2.8x#2 | 4.3%#4 | 186.0%#1 | 12.5%#1 | 18.2%#1 | 5.8%#1 | 7#1 | — | — |
| TLPPF | — | — | — | — | 55.6%#1 | -121.2%#5 | 3.7%#2 | — | — | — | — | — |
| TLSA | $83M#4 | — | — | — | — | 32.9%#3 | — | — | — | — | -63.9%#2 | — |
| TLX | $3.1B#2 | — | — | 3.8x#3 | 55.6%#1 | -121.2%#5 | 3.7%#2 | — | — | — | — | — |
| UPC | $875991#5 | — | 0.0x#1 | 0.0x#1 | -22.4%#5 | 57.9%#2 | -16.3%#4 | -6.5%#2 | -4.6%#2 | — | — | 1827.1%#1 |
| URGN | $1.6B#3 | — | — | 14.7x#4 | 21.4%#3 | -21.0%#4 | -113.7%#5 | — | — | 2#2 | 61.2%#1 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-02.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice